All News

lupus SLE

Social Determinants of Health in SLE

EurekAlert!

Social determinants of health (SDH), such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases.

Read Article
Conv3.jpg

EULAR 2025 - Day 1 Report

Jack Cush, MD

Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.

Read Article
early.ra_.2.jpg

2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia

Jack Cush, MD

A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA).

Read Article
RheumNow Podcast square

MTX Fails Knee OA (6.6.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Read Article
labs2.jpg

HLA-B27 Testing in Practice

Jack Cush, MD

Analysis of testing for human leukocyte antigen B27 (HLA-B27) in a teaching center shows HLA-B27 testing was frequently performed by rheumatologists and nonrheumatologists for a broad spectrum of indications and primarily as a screening test. 

Read Article
osteoporosis.OP_.Drugs_.jpg

Denosumab and Osteoporosis - A JAMA Review

Jack Cush, MD

An overview of denosumab use in osteoporosis (OP)  by Bauer and Ensrud was published in JAMA. 

Read Article
RheumNow Podcast square

Moneyball Rheumatology (5.30.2025)

Jack Cush, MD

Dr. Jack Cush reviews the book/movie, "Moneyball" and a suggests moneyball strategy is needed to find next level responses for our patients.

Read Article
syringe, pill, DMARD, Treatment, therapy

Tocilizumab vs. Methotrexate in Rheumatoid Arthritis

Jack Cush, MD

A large randomized rheumatoid arthritis (RA) clinical trial compared subcutaneous tocilizumab (TCZ) vs oral methotrexate (MTX) vs. the combination of subcutaneous TCZ and MTX, and showed that TCZ was superior to MTX, either given as TCZ monotherapy or in combination with MTX. 

Read Article
Biologic.choice.MD_.jpeg (keep)

Biologics in Pregnancy Patients With Autoimmune Disease

Jack Cush, MD

A large cohort, claims data study shows that among pregnant women receiving biologic therapies for autoimmune conditions, 72% continued their biologics pregnancy, more so among inflammatory bowel disease (IBD) patients than those with rheumatoid arthritis (RA), psoriasis (PsO) or psoriatic arthri

Read Article
VitD_1.jpg

D-Lay Trial: High-Dose Vitamin D Retards Multiple Sclerosis

Jack Cush, MD

A randomized clinical trial with oral high-dose cholecalciferol ( vitamin D3) was shown to prevent or delay the onset of clinically isolated syndrome (CIS), typical for multiple sclerosis (MS).

Read Article
RheumNow Podcast square

Keys to Mastery (5.2.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, articles and drug approvals from the past week on RheumNow.com. This podcast marks the beginning of our Lupus Campaign called "Lupus Unlocked: Keys to Mastery". This month's campaign on Lupus is sponsored by Aurinia.

Read Article
Rheumatoid,RA,nodules,damage

Complex Evolution of RA Management and Outcomes

Jack Cush, MD

FIRST is a Japanese longitudinal, real-world registry of rheumatoid arthritis (RA) management, and over the last 20 years has shown significantly improved outcomes, yet significant challenges and unmet needs remain.

Read Article
@RheumNow Achieving health equity is the goal 1.4% of GDP is lost in health inequity in EU https://t.co/50M4SfuxvX

Links:

Bella Mehta bella_mehta ( View Tweet)
How much of the health outcomes are related to social determinants? 🔺️Up to 75%! Disaster Medicine Session Social disparities and impact on outcomes Dr Kate Webb #EULAR2025 @RheumNow https://t.co/0Ahbf79Nbx

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
What do we know about disparities in #SLE - worse in women - worse in non white populations - have lower quality of care in vulnerable populations - have worse outcomes in vulnerable populations #EULAR2025 @rheumnow Diagnosis itself is difficult in communities with poor access https://t.co/pcUaJ0eK65

Links:

Bella Mehta bella_mehta ( View Tweet)
#Lupus is one of the biggest social discriminators 🔺️Higher prevalence in Women 🔺️Higher prevalence in Non-Whites 🔺️More catastrophic manifestations in low socioeconomic groups Disaster Medicine Session Social disparities and impact on outcomes #EULAR2025 @RheumNow https://t.co/mewR9NzXHt

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Delay hurts. Dx delay in axial SpA costs UK £3.1 billion annually. Avg time to dx = 8.5 yrs Avg dx cost = £187k/person Fixing delay could save £167k/person. Early Dx isn’t just better care—it’s economic policy. #EULAR2025 @RheumNow #AxialSpA #RMD https://t.co/eYEQ2rp94m

Links:

Jiha Lee JihaRheum ( View Tweet)
Premature death in RA still exists, and varies according to race/ethnicity demographic groups Nationwide US CDC's MCoD database analysis -Mortality rates 11x higher American Indians 3x higher Black or African American people -Median age at death with RA 9-10 years younger https://t.co/FTRWPk7Wz0

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Access inequity across Europe is real. New #RheumaFacts data show major gaps in RMD care: 🔹 Full tsDMARD access in just 4% of countries 🔹 Self-referral possible in 57% 🔹 Rheum physio reimbursed in 63% 🔹 Psych care? Only 30%. Abstract#OP0025 @RheumNow #EULAR2025

Jiha Lee JihaRheum ( View Tweet)

Debuting Fishbowl sessions at #EULAR2025 🔄💊 Lively audience engaging session in A1 on how drug prices influence treatment decisions; real-world tensions between cost, access, & physician autonomy. Transparent, interactive, and packed! @RheumNow | Location: A1 | #EULAR2025 https://t.co/jVbviLuTZK

Links:

Jiha Lee JihaRheum ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×